Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. - Wikidata - awgldk - TriplyDB

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.

http://www.wikidata.org/entity/Q41361742

about

Oncolytic virus therapy: A new era of cancer treatment at dawn Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants Going viral: a review of replication-selective oncolytic adenoviruses Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances Activation of p53 by chemotherapeutic agents enhances reovirus oncolysis A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives High efficiency of alphaviral gene transfer in combination with 5-fluorouracil in a mouse mammary tumor model.Viruses in cancer treatment.Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma.Enhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150/signaling lymphocytic activation molecule.Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.Oncolysis by paramyxoviruses: preclinical and clinical studies.Naturally occurring reoviruses for human cancer therapy.Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor The art of gene therapy for glioma: a review of the challenging road to the bedside Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer.Trial watch: Oncolytic viruses for cancer therapy Reovirus in cancer therapy: an evidence-based review Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.Reovirus: a targeted therapeutic--progress and potential.Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.Maraba virus as a potent oncolytic vaccine vector.Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling.

P2860

Q26739714-E525CC86-366A-4DF7-8ECC-D8F154CF21F7 Q26750568-29E4935A-F820-465F-8F86-2C533B3D3AFB Q26752807-0F649695-F77B-4515-B4BF-91B97419A1B9 Q26775030-F9C42578-71DF-44A9-88CB-A50E1DEBD1F5 Q26775033-FEC8BDA3-BC65-4D3B-9719-5DC90120B245 Q26797520-0F7BADE0-16E5-40DB-A357-BAA588969F2E Q26852345-DE82C1AE-6977-4D3F-96B6-720D935A9E19 Q26863779-3123267E-6F94-4E2F-9744-5B97A4FAD6AD Q28485141-9158CEB8-9AFF-4215-A9AE-9D24003E5C0F Q33418048-0E1F0FC7-AE15-4C40-BD5A-4C19BBF2804C Q33551626-DED0684B-8B73-4AA6-B839-9C536DD2E063 Q33670728-DBB2673F-D030-4228-896F-32DF20FBAFB1 Q33679505-CE93D40C-B348-4540-80B9-4988E96AA6A1 Q33828697-F24B2624-2BD8-4F78-A781-4AE139B03653 Q34311097-A8D3BE09-14C0-4751-84CC-D151F425B3FB Q34393001-5364E7BA-DC0D-495B-B691-48B0D91FA628 Q34662879-95A80556-5EE6-4215-9FFE-64DC8284D6E9 Q35051487-E1B758CC-17A6-4B3D-964B-CCD778F6D3E6 Q35061974-B40E1167-3E12-4210-A631-5F75850208B7 Q35224368-FEBAE206-90C4-4262-A366-08F9B3D4F5F7 Q35686522-D89AF507-9E1B-4941-A62F-EF8F8F9EE5C0 Q35812675-60B4269D-8FC6-4044-86EA-208B00FE9B5D Q35861933-5837CACF-8D73-47AD-95BC-09F745AC59AE Q36078485-A6B9F19C-9D13-4B96-9CE4-040151CAFFFE Q36298608-7512AF31-CAC2-4233-8404-F09727146CEF Q36390114-2B3846F0-870E-4478-81CF-018950CB9C5B Q36527593-33C499E0-8F43-46F3-9270-FEC16732E20D Q36766032-A0AAA887-2F55-49F3-9D43-9047CFE30492 Q36766052-326740C3-325A-4A3B-910E-3D59AC3F550D Q36971463-B2D5F267-5A8F-447D-89D7-998E02138AFC Q37028023-670F37CB-B2E4-4424-B27C-E6E545B44612 Q37031909-35A050C8-BA68-4485-9537-999317B95E42 Q37062074-F4360F4F-BA22-4CD1-9164-56D242350978 Q37124552-679255EA-56CE-4D1F-BA1E-81AEE1DE75FC Q37347236-95850ED4-C831-4B2B-8B8B-DE3ACF944954 Q37360608-5D206B77-FFD0-4790-9C2D-3941DBFDF883 Q37459636-3740CF80-472F-49A1-9D1B-70AEAE4690AD Q37477557-BAE489BF-4334-44D4-8D34-41875F30F0F2 Q37562080-B1EC1521-43C7-4E3F-B133-872ABD52D8BD Q37565521-083FEB4A-E809-460D-B0C8-6650787E3C4E

P2860

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.

http://www.wikidata.org/entity/Q41361742

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Phase I/II trial of carboplati ...... ts with advanced malignancies.

@en

type

label

Phase I/II trial of carboplati ...... ts with advanced malignancies.

@en

prefLabel

Phase I/II trial of carboplati ...... ts with advanced malignancies.

@en

P1433

Q41361742-1724A6F1-E74F-4DC8-B624-DB89CF170BDE

P1476

Q41361742-DC4ED4A8-41BD-497C-BBB9-40BA3FA6A312

P2093

Q41361742-0DE66219-530A-4805-9D4A-029742482D0E

Q41361742-13E035C1-D1D0-467D-9ADE-DC038261A183

Q41361742-28B553D6-C3AC-4C37-9CF1-45B5E4B128C2

Q41361742-2A38E213-0A4A-4581-9A07-44242188D2AE

Q41361742-3A0A5668-13D8-4218-9848-FCFC0555D82A

Q41361742-4FA2F90D-4BB3-45AB-B0E6-C8FA40D04F98

Q41361742-5B724B38-074B-4D8A-B2E6-7554C378E94F

Q41361742-6970BA81-2B24-4127-821E-8DA2B33E945C

Q41361742-72107AD3-2BDC-49ED-BC87-DA780071B350

Q41361742-8928B5B9-26DB-45C1-9D67-55BCB561EC30

P2860

Q41361742-194B2126-23C9-48AD-B76E-8F6C9EF702DE

Q41361742-1DE9C4E8-0B4A-48DB-966C-E148540DE882

Q41361742-393E4A40-CD72-4D0F-8876-23A3BA77C280

Q41361742-3C27CF17-1698-49A1-9FCF-4CF91C8A1997

Q41361742-40EA527C-7A3E-4D5A-8C3C-E9E5385E0B1A

Q41361742-423937D5-1BF3-4C90-9A5F-3C9DE4038B61

Q41361742-4D8E4A91-E316-492D-92F7-2A5539634C3E

Q41361742-64E45009-EB3C-4585-A970-54835E67334C

Q41361742-6C8075FF-2D6E-4CE4-9C3A-8223E4D4BC16

Q41361742-8076E80F-9FEB-41C1-A3A6-3BF1A72B516F

P304

Q41361742-82C9652B-AE0F-4E04-90F6-49AD6B9BEFB8

P31

Q41361742-05DF4932-C9BC-48F4-8178-14227F1CEAC3

P356

Q41361742-9022FE34-B66B-4457-AC3F-376994BCD6FC

P407

Q41361742-8B538327-F151-40E9-BC4A-5933F1884368

P433

Q41361742-7509C22E-0D82-459D-84FE-64A96BBB228B

P478

Q41361742-3960CFC2-83DA-4EA6-A442-A21E631A5D8D

P577

Q41361742-60DE7446-C5C5-4148-847D-9AE53EF1FCB9

P698

Q41361742-33684983-DCE5-4C87-8F0F-A17B66780A49

P921

Q41361742-2C46342F-1426-40E9-8C99-B926393D87FA

Q41361742-520C467B-C67E-411E-958E-5935684C7DAB

Q41361742-60A1E934-4D4D-4632-B71D-3EBA134CB2CB

Q41361742-C293539F-A668-4533-B809-657434658450

P932

Q41361742-466DDCDE-A2B5-4F33-A3F6-E651FB2FB8FB

P356

1078-0432.CCR-11-2181

P1433

Clinical Cancer Research

P1476

Phase I/II trial of carboplati ...... ts with advanced malignancies.

@en

P2093

Alan A Melcher

http://www.w3.org/2001/XMLSchema#string

Brad Thompson

http://www.w3.org/2001/XMLSchema#string

Chris Nutting

http://www.w3.org/2001/XMLSchema#string

Eleni M Karapanagiotou

http://www.w3.org/2001/XMLSchema#string

Geoff D Hall

http://www.w3.org/2001/XMLSchema#string

Hardev S Pandha

http://www.w3.org/2001/XMLSchema#string

James Larkin

http://www.w3.org/2001/XMLSchema#string

John Chester

http://www.w3.org/2001/XMLSchema#string

Karl Mettinger

http://www.w3.org/2001/XMLSchema#string

Kate Newbold

http://www.w3.org/2001/XMLSchema#string

P2860

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic.

A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.

Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma.

Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.

P304

2080-2089

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-2181

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22316603

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

phase I clinical trial

phase II clinical trial

P932

5553618

http://www.w3.org/2001/XMLSchema#string